Frank Campana

3.1k total citations
52 papers, 1.2k citations indexed

About

Frank Campana is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Frank Campana has authored 52 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 31 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Frank Campana's work include Multiple Myeloma Research and Treatments (34 papers), Peptidase Inhibition and Analysis (23 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Frank Campana is often cited by papers focused on Multiple Myeloma Research and Treatments (34 papers), Peptidase Inhibition and Analysis (23 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Frank Campana collaborates with scholars based in United States, France and Spain. Frank Campana's co-authors include Paul G. Richardson, Kenneth C. Anderson, Thomas G. Martin, Don M. Benson, Nikoletta Lendvai, Éric Charpentier, Ravi Vij, Rachid Baz, Helgi van de Velde and Jeffrey L. Wolf and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Frank Campana

51 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frank Campana United States	19	696	635	537	230	148	52	1.2k
Iman Jilani United States	21	308 0.4×	565 0.9×	578 1.1×	203 0.9×	814 5.5×	54	1.6k
J. Garcia‐Vargas United States	13	495 0.7×	169 0.3×	503 0.9×	249 1.1×	154 1.0×	62	1.2k
Craig E. Cole United States	14	539 0.8×	497 0.8×	433 0.8×	65 0.3×	321 2.2×	48	1.1k
Mirosław Majewski Poland	16	456 0.7×	308 0.5×	522 1.0×	22 0.1×	279 1.9×	28	1.4k
Laurence Lodé France	16	429 0.6×	848 1.3×	878 1.6×	55 0.2×	209 1.4×	30	1.3k
Nathalie Bardy‐Bouxin United States	10	364 0.5×	481 0.8×	425 0.8×	51 0.2×	401 2.7×	20	1.1k
Michael Arbushites United States	15	1.2k 1.7×	319 0.5×	381 0.7×	423 1.8×	268 1.8×	32	1.7k
Jerzy Z. Błoński Poland	21	291 0.4×	151 0.2×	224 0.4×	70 0.3×	797 5.4×	75	1.2k
Kathleen Turnbull United States	11	599 0.9×	259 0.4×	292 0.5×	225 1.0×	268 1.8×	21	999
Amber Gordon United States	8	340 0.5×	357 0.6×	432 0.8×	65 0.3×	1.2k 7.9×	14	1.5k

Countries citing papers authored by Frank Campana

Since Specialization

Citations

This map shows the geographic impact of Frank Campana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Campana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Campana more than expected).

Fields of papers citing papers by Frank Campana

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Campana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Campana. The network helps show where Frank Campana may publish in the future.

Co-authorship network of co-authors of Frank Campana

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Campana. A scholar is included among the top collaborators of Frank Campana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Campana. Frank Campana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sunami, Kazutaka, Takashi Ikeda, Shang‐Yi Huang, et al.. (2022). Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. Clinical Lymphoma Myeloma & Leukemia. 22(8). e751–e761. 5 indexed citations

Harrison, Simon J., Aurore Perrot, Adrían Alegre, et al.. (2021). Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics. British Journal of Haematology. 194(1). 120–131. 32 indexed citations

Franklin, Anna R., Mara Albonei Dudeque Pianovski, Franca Fagioli, et al.. (2021). AN OPEN‐LABEL, PHASE 1/2 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN + ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE IN PAEDIATRIC PATIENTS WITH ADVANCED STAGE HODGKIN LYMPHOMA. Hematological Oncology. 39(S2). 2 indexed citations

Bringhen, Sara, Luděk Pour, Vladimir Vorobyev, et al.. (2021). Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leukemia Research. 104. 106576–106576. 20 indexed citations

Usmani, Saad Z., Chatchada Karanes, William Bensinger, et al.. (2021). Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 35(12). 3526–3533. 16 indexed citations

Capra, Marcelo, Meral Beksaç, Paul G. Richardson, et al.. (2020). ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS. Hematology Transfusion and Cell Therapy. 42. 263–264. 4 indexed citations

Usmani, Saad Z., Chatchada Karanes, William Bensinger, et al.. (2019). Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study. Clinical Lymphoma Myeloma & Leukemia. 19(10). e283–e283. 2 indexed citations

Martin, Thomas G., Marielle Chiron, Helgi van de Velde, et al.. (2019). Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells. 8(12). 1522–1522. 106 indexed citations

Richardson, Paul G., Joseph Mıkhael, Thierry Façon, et al.. (2019). The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies. Blood. 134(Supplement_1). 3179–3179. 1 indexed citations

10.

Martin, Thomas G., Rachid Baz, Don M. Benson, et al.. (2017). A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 129(25). 3294–3303. 134 indexed citations

11.

Richardson, Paul, Joseph Mıkhael, Saad Z. Usmani, et al.. (2017). Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 17(1). e16–e17. 19 indexed citations

12.

Blackwell, Kimberly, Howard A. Burris, Patricia Gómez, et al.. (2015). Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. Breast Cancer Research and Treatment. 154(2). 287–297. 30 indexed citations

13.

Belin, Lisa, P. Cottu, P. Bontemps, et al.. (2015). Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer. British Journal of Radiology. 88(1048). 20140800–20140800. 9 indexed citations

14.

Tolaney, Sara M., Howard A. Burris, Elaina M. Gartner, et al.. (2014). Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 149(1). 151–161. 49 indexed citations

15.

Matulonis, Ursula A., Ignace Vergote, Floor Backes, et al.. (2014). Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecologic Oncology. 136(2). 246–253. 88 indexed citations

16.

Baz, Rachid, Don M. Benson, Nikoletta Lendvai, et al.. (2014). A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood. 124(21). 83–83. 32 indexed citations

17.

Gómez, Henry, Frank Campana, Silvia P. Neciosup, et al.. (2012). Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma. Hematology/Oncology and Stem Cell Therapy. 5(3). 152–157. 1 indexed citations

18.

Extra, Jean-Marc, Anne Vincent‐Salomon, T. Delozier, et al.. (2010). Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study. The Oncologist. 15(8). 799–809. 92 indexed citations

19.

Giraud, P., F Reboul, Sébastien Clippe, et al.. (2003). [Respiration-gated radiotherapy: current techniques and potential benefits].. PubMed. 7 Suppl 1. 15s–25s. 28 indexed citations

20.

Rochefordière, Anne de la, Suzy Scholl, Philippe Broët, et al.. (1995). 142 Role of metachronous contralateral breast carcinoma in the outcome of breast cancer. International Journal of Radiation Oncology*Biology*Physics. 32. 212–212. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact